Eli Lilly (LLY) Gains from Investment Securities (2016 - 2025)
Eli Lilly's Gains from Investment Securities history spans 17 years, with the latest figure at -$56.8 million for Q4 2025.
- For Q4 2025, Gains from Investment Securities fell 108.38% year-over-year to -$56.8 million; the TTM value through Dec 2025 reached -$1.0 million, down 100.4%, while the annual FY2025 figure was -$1.0 million, 100.4% down from the prior year.
- Gains from Investment Securities reached -$56.8 million in Q4 2025 per LLY's latest filing, up from -$312.1 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $678.2 million in Q4 2024 to a low of -$680.3 million in Q3 2024.
- Average Gains from Investment Securities over 5 years is $88.5 million, with a median of $116.9 million recorded in 2022.
- The largest YoY upside for Gains from Investment Securities was 705.56% in 2023 against a maximum downside of 439.12% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at $189.0 million in 2021, then surged by 40.79% to $266.1 million in 2022, then surged by 111.16% to $561.9 million in 2023, then rose by 20.7% to $678.2 million in 2024, then plummeted by 108.38% to -$56.8 million in 2025.
- Per Business Quant, the three most recent readings for LLY's Gains from Investment Securities are -$56.8 million (Q4 2025), -$312.1 million (Q3 2025), and $171.2 million (Q2 2025).